Citable segment mix
MCK's latest SEC segment disclosure for revenue by segment shows North American Pharmaceutical as the largest listed segment at $86.77B (82.3% of disclosed segment revenue).
| Segment | Period | Revenue | Mix |
|---|---|---|---|
| North American Pharmaceutical | Jun 30, 2026 | $86.77B | 82.3% |
| Oncology & Multispecialty | Jun 30, 2026 | $14.22B | 13.5% |
| Medical-Surgical Solutions | Jun 30, 2026 | $2.82B | 2.7% |
| Prescription Technology Solutions | Jun 30, 2026 | $1.57B | 1.5% |
Source: SEC EDGAR segment disclosures; period Jun 30, 2026.
MCK company research is free during early access. All you need is an account, with no card required. The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay open without one.
Continue research
Follow same-sector companies and source explainers connected to the segments view.
A factual guide to revenue segment disclosures and how Aerarium Research uses them to make company business mix easier to inspect.
A factual guide to seasonal revenue patterns and comparable (same-store) sales — why year-over-year comparisons matter and what comp sales strip out.
A factual guide to deferred revenue, cash collected before revenue is earned, and why the liability can matter for recurring businesses.
A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.